A landmark joint workshop convened by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) this morning, September 25, 2026, aimed to harmonize and clarify the intricate pathways for bringing botanical drugs to market in both North America and Europe. Held at the EMA headquarters in Amsterdam, the session, despite an early start for North American attendees, drew a significant global audience of over 1,000 participants, underscoring the burgeoning international interest in this specialized therapeutic category. The collaborative effort sought to identify common ground and propose solutions to streamline the development and approval process for medicinal products derived from plant sources, a sector experiencing notable growth.
The day’s proceedings kicked off with an examination of the escalating demand and inherent importance of botanical health products. Stefan Gafner, Chief Science Officer at the American Botanical Council (ABC), presented compelling data illustrating the rapid ascent of herbal product sales within the United States. His findings also highlighted a critical distinction: botanical drug products regulated under the European Union’s framework demonstrate a significantly lower incidence of adulteration compared to their counterparts marketed as dietary supplements in the U.S. This observation points to potential structural advantages within the EU’s regulatory system for ensuring product integrity.
The session further elucidated the crucial role of healthcare professionals in the dissemination of botanical medicines. Jorge Batista, representing a consortium of community pharmacies, detailed the established practices and responsibilities of pharmacists in administering botanical drugs across various European member states. Offering a consumer-centric perspective, Dominique Hamerlijnck of the European Lung Foundation articulated the current challenges faced by patients in accessing vital information regarding botanical drugs. She noted that while data on potential drug interactions and other crucial safety aspects exists, its scattered nature across multiple websites and often technical categorization under Latin binomial species names makes it exceedingly difficult for the average consumer to locate and comprehend. This fragmentation of information poses a significant barrier to informed patient decision-making and adherence.
The core of the workshop then shifted to a deep dive into the regulatory landscapes of the United States and the European Union, featuring high-level administrators from both agencies. Cassandra Taylor of the FDA outlined the U.S. regulatory architecture, which is firmly rooted in the Food, Drug, and Cosmetic (FD&C) Act and further refined through a comprehensive body of regulations and guidance documents. This framework typically necessitates extensive preclinical and clinical data, with a strong emphasis on rigorous scientific substantiation of both safety and efficacy.
In contrast, Carmen Purdel, Chair of the EMA’s Committee for Herbal Medicinal Products (HMPC), described a more "bottom-up" approach prevalent in the EU. This system often leverages existing safety data derived from products with a long history of use within the EU, often falling under various traditional herbal designations. The EMA’s framework also considers the scope of market access desired by the applicant, differentiating between applications seeking approval for the entire EU market versus those targeting specific member states. This modular approach can offer flexibility, though it also introduces a layer of complexity depending on the intended geographical reach.
A pivotal case study was then presented, examining the divergent approval processes for FILSUVEZ, a drug derived from a birch extract comprising a complex of birch triterpenes, used for treating a rare skin disease. Charles Wu from the FDA detailed the U.S. approval, emphasizing the agency’s stringent requirements for comprehensive characterization of the active substance. The FDA placed a significant onus on demonstrating manufacturing consistency, ensuring minimal batch-to-batch variation through robust quality control measures. Jacqueline Wiesner of the EMA’s HMPC presented the EU’s perspective, highlighting that the European approval required standardization to a single terpene component, indicating a less demanding analytical and manufacturing control standard in that specific instance. This stark contrast underscores the differing philosophies and requirements inherent in each regulatory system.
The economic implications of these divergent regulatory pathways were a significant undercurrent throughout the discussions. While not explicitly detailed in every presentation, it is widely acknowledged within the industry that the U.S. approval process for botanical drugs is considerably more arduous and costly, potentially exceeding the financial outlay in the EU by a factor of ten. This disparity has contributed to a low number of botanical drug approvals in the United States over several decades, with numerous submissions reportedly faltering due to an inability to meet the FDA’s exacting quality and characterization standards. This economic hurdle acts as a significant deterrent for innovation and investment in this space within the U.S.
The workshop culminated in a dynamic panel discussion that brought together key stakeholders from industry and regulatory advocacy groups. Participants included Angela Mueller and Christelle Anquez-Traxler from the Association of the European Self-Care Industry (AESGP), Holly Johnson representing the American Herbal Products Association (AHPA), and Susan Winckler of the Reagan Udall Foundation for the FDA. A prominent suggestion that emerged from this dialogue was the potential creation of an intermediate regulatory category in the U.S., situated between conventional pharmaceuticals and dietary supplements, specifically for botanical drugs. However, Winckler cautioned that such a reform would necessitate an amendment to the FD&C Act, a prospect she deemed unlikely in the current legislative climate. Another frequently cited recommendation, common across many such industry forums, was the call for increased, targeted research and greater public funding to support scientific exploration in the botanical drug arena.
Roy Upton, founder of the American Herbal Pharmacopoeia, who has been closely monitoring the renewed impetus for botanical drug development, provided a thoughtful written commentary on the day’s proceedings. His observations offered a broader perspective on the implications for the broader herbal products market. Upton acknowledged the workshop’s success in showcasing "growing international interest in the development and regulation of botanical medicinal products and highlighted both significant opportunities and substantial challenges."
He elaborated on the central themes that resonated throughout the discussions: "The central themes included the importance of safety, efficacy, quality, pharmacovigilance, real-world evidence, appropriate regulatory pathways, education, transparency, and collaboration." Upton’s assessment also underscored the value of cross-jurisdictional learning, stating, "The discussion also underscored the value of learning from existing regulatory experience, particularly the more than two decades of experience within the European system, while recognizing the distinct statutory and regulatory environment in the United States." His insights suggest a need for a nuanced approach that leverages global best practices while respecting the unique legal and operational frameworks of each region.
The organizers confirmed that a recording of the comprehensive session would be made available to all registered participants who were unable to attend in person, ensuring that the valuable insights and discussions would have a lasting impact and broad reach within the global scientific and regulatory communities. This initiative represents a significant step forward in fostering a more cohesive and efficient environment for the advancement of botanical medicines, potentially leading to greater patient access to novel plant-derived therapies. The collaborative spirit demonstrated by the FDA and EMA signals a commitment to overcoming the inherent complexities of this specialized field, paving the way for future innovation and improved public health outcomes. The continued dialogue and potential for future joint initiatives hold promise for bridging the regulatory divide and unlocking the full therapeutic potential of botanicals on a global scale.
